An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Eragidomide (Primary) ; Gilteritinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
Most Recent Events
- 30 May 2024 Status changed from active, no longer recruiting to discontinued.
- 22 Sep 2023 Planned End Date changed from 25 Jan 2025 to 6 Oct 2025.
- 22 Sep 2023 Planned primary completion date changed from 26 Jan 2024 to 6 Oct 2023.